Literature DB >> 2859898

Cytochemistry of dipeptidylaminopeptidase IV and II in normal and neoplastic lymphoid cells.

R Invernizzi, G Bertolino, M Girino, P Perseghin, M Michienzi, R Nano.   

Abstract

Cytochemical methods were used to determine the distribution of dipeptidylaminopeptidase IV (DAP IV) and II (DAP II) in lymphoid cell populations from patients with lymphoproliferative diseases. Special attention was paid to unusual intracellular distribution patterns which might correlate with the presence of various membrane markers. In healthy patients, about 50% of the circulating lymphocytes were found to be positive to both reactions, the intracellular distribution patterns being variable. The DAP IV reaction was negative in all B-CLL cases. In 2 cases of T-CLL with phenotype E+ OKT3+T4-T8+ one was negative and one was weakly positive, while two cases of T-CLL with phenotype E+ OKT3+T4+T8- were both strongly positive. The other non-T lymphoproliferative diseases studied were negative for DAP IV, while one T-ALL and three T-lymphoma cases showed a strong granular or diffuse distribution. The DAP II reaction was strongly positive in all the T lymphoproliferative diseases studied, irrespective of their immunological phenotype. This reaction was also weakly positive in some cases of plasmocytoma and lymphoplasmacytoid lymphoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859898     DOI: 10.1007/bf00319753

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  23 in total

1.  Formation of mouse or sheep red-blood-cell rosettes by lymphocytes from normal and leukaemic individuals.

Authors:  G Stathopoulos; E V Elliott
Journal:  Lancet       Date:  1974-04-06       Impact factor: 79.321

2.  Subtyping of chronic lymphocytic leukemia of T-type by dipeptidylaminopeptidase IV (DAP IV), monoclonal antibodies, and Fc-receptors.

Authors:  A C Feller; M R Parwaresch; K Lennert
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

3.  Separation of functional subsets of human T cells by a monoclonal antibody.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

4.  Study on aminopeptidase A.

Authors:  Z Lojda; R Gossrau
Journal:  Histochemistry       Date:  1980

5.  Acid hydrolases as markers of maturation in B-cell chronic lymphocytic leukemia.

Authors:  C E Grossi; A Zicca; A Leprini; A Cadoni; V Pistoia; M Ferrarini
Journal:  Blood       Date:  1982-07       Impact factor: 22.113

Review 6.  B and T cell markers in human proliferative blood diseases and primary immunodeficiencies, with special reference to membrane bound immunoglobulins.

Authors:  M Seligmann; J L Preud'Homme; J C Brouet
Journal:  Transplant Rev       Date:  1973

7.  Dipeptidyl(amino)peptidase IV (DAP-IV) histochemistry on normal and pathologic lymphoid tissues.

Authors:  M Chilosi; G Pizzolo; F Menestrina; A M Iannucci; F Bonetti; L Fiore-Donati
Journal:  Am J Clin Pathol       Date:  1982-06       Impact factor: 2.493

8.  Dipeptidylaminopeptidase IV activity in normal and leukemic T-cell subpopulations.

Authors:  A D Crockard; E MacFarlane; C Andrews; J M Bridges; D Catovsky
Journal:  Am J Clin Pathol       Date:  1984-09       Impact factor: 2.493

9.  Dipeptidylaminopeptidase IV (DAP IV) activity in normal and malignant T-cell subsets as defined by monoclonal antibodies.

Authors:  R Wirthmüller; D Dennig; J Oertel; H Gerhartz
Journal:  Scand J Haematol       Date:  1983-09

10.  Proteinases in pathology. Usefulness of histochemical methods.

Authors:  Z Lojda
Journal:  J Histochem Cytochem       Date:  1981-03       Impact factor: 2.479

View more
  2 in total

1.  Comparative cytochemical study of dipeptidyl aminopeptidase (DAP) II and IV in normal and malignant haemic cells.

Authors:  M R Khalaf; P C Bevan; F G Hayhoe
Journal:  J Clin Pathol       Date:  1986-08       Impact factor: 3.411

2.  Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia.

Authors:  B Bauvois; I De Meester; J Dumont; D Rouillard; H X Zhao; E Bosmans
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.